Drug Profile


Alternative Names: AFP-CAR; alpha-fetoprotein-chimeric antigen receptor

Latest Information Update: 16 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eureka Therapeutics
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Hepatocellular carcinoma

Highest Development Phases

  • Preclinical Hepatocellular carcinoma

Most Recent Events

  • 14 Jun 2017 ET1402L1-CAR is available for licensing as of 14 Jun 2017.
  • 07 Jun 2017 Preclinical trials in Hepatocellular carcinoma in USA (Parenteral)
  • 07 Jun 2017 Eureka Therapeutics and City of Hope plans a phase I trial for Hepatocellular carcinoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top